HealthCare Global Enterprises Limited (HCG) announced its unaudited financial results for the second quarter and first half of FY27. Revenue for Q2 FY27 grew by 16% year-on-year to INR 7,318 million. The company highlighted growth across its clusters, driven by increased patient volumes and ARPP. EBITDA saw a 17% year-on-year increase, reaching INR 1,425 million.
HCG Q2 and H1 FY27 Earnings Call Transcript Highlights
HealthCare Global Enterprises Limited (HCG) held its earnings conference call on November 06, 2026, to discuss its unaudited financial results for the second quarter and first half of FY27. The company reported a sustained growth momentum, with Q2 FY27 revenue reaching INR 7,318 million, a 16% increase year-on-year. This growth was attributed to healthy patient demand and an improving revenue mix.
Financial Performance
For Q2 FY27, HCG’s revenue growth, excluding the North Bengaluru new hospital, stood at 14% year-on-year. The overall growth was driven by a 9% increase in patient volumes and a 7% rise in average revenue per patient (ARPP). EBITDA for the quarter, including the North Bengaluru loss, was INR 1,425 million, marking a 17% year-on-year growth, with EBITDA margins improving to 19.7% from 19.2% in Q2 FY26. The company also noted an ESOP expense of INR 29.8 million recognized during the quarter.
First Half FY27 Performance
Consolidated revenue for the first half of FY27 (H1 FY27) stood at INR 14,100 million, an increase of 15% year-on-year. This growth was powered by a 9% rise in patient volume and a 6% increase in ARPP. Adjusted EBITDA for H1 FY27 grew by 18% year-on-year to INR 2,740 million, with margins improving to 19.7%. Finance costs declined by 11% year-on-year to INR 775 million. Adjusted PAT for H1 FY27 was INR 287 million, a 30% year-on-year growth.
Operational Highlights and Strategic Priorities
HCG’s strategic priorities continue to focus on profitable growth, improving asset utilization, strengthening clinical differentiation, and optimizing its revenue mix. The company highlighted progress in expanding its non-institutional business, which grew by 21% year-on-year, contributing 69% to revenue share. Investments in advanced medical technologies included the operationalization of an MR-LINAC system and a cardiac surgical robotic system. Key clinical milestones included the first CAR T-cell therapy and new robotic surgeries across various centers.
Cluster Performance
The South cluster reported revenue of INR 2,941 million, with 18% growth. The West cluster generated INR 3,147 million, showing 10% year-on-year growth. The East cluster saw revenue of INR 928 million, a 23% year-on-year increase. International operations in Kenya registered approximately 54% year-on-year growth.
Regulatory Developments
The company also addressed regulatory developments concerning trade margins on non-scheduled anti-cancer drugs, estimating a mid-to-high single-digit percentage impact to EBITDA on an annualized basis. While acknowledging a potential near-term impact, HCG expressed confidence in its underlying growth drivers and strategic initiatives.
Source: BSE
